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Abstract Obesity is a risk factor for the development of
new cases of breast cancer and also affects survival in
women who have already been diagnosed with breast can-
cer. Early studies of obesity and breast cancer survival have
been summarised in two meta-analyses, but the latest of
these only included studies that recruited women diagnosed
as recently as 1991. The primary aim of this study was to
conduct a meta-analysis that included the more recent
studies. A systematic search of MEDLINE, EMBASE and
CINAHL was conducted to identify original data evaluating
the effects of obesity on survival in newly diagnosed breast
cancer patients. Adjusted hazard ratios (HR) from individual
studies were pooled using a random effects model. A series
of pre-specified sensitivity analyses were conducted on
factors such as overall versus breast cancer survival and
treatment versus observational cohort. The meta-analysis
included 43 studies that enrolled women diagnosed with
breast cancer between 1963 and 2005. Sample size ranged
from 100 to 424168 (median 1192). The meta-analysis
showed poorer survival among obese compared with non-
obese women with breast cancer, which was similar for
overall (HR = 1.33; 95% confidence interval (CI): 1.21,
1.47) and breast cancer specific survival (HR = 1.33; 95%
CI: 1.19, 1.50). The survival differential varied only slightly,
depending on whether body mass index (1.33; 1.21, 1.47) or
waist–hip ratio (1.31; 1.08, 1.58) was used as the measure of
obesity. There were larger differences by whether the
woman was pre-menopausal (1.47) or post-menopausal
(1.22); whether the cohort included women diagnosed
before (1.31) or after 1995 (1.49); or whether the women
were in a treatment (1.22) or observational cohort (1.36), but
none of the differences were statistically significant. Women
with breast cancer, who are obese, have poorer survival than
women with breast cancer, who are not obese. However, no
study has elucidated the causal mechanism and there is
currently no evidence that weight loss after diagnosis
improves survival. Consequently, there is currently no rea-
son to place the additional burden of weight loss on women
already burdened with a diagnosis of cancer. Further
research should concentrate on assessing whether factors
such as diabetes or type of chemotherapy modify the obesity
effect and on understanding the causal mechanism, in par-
ticular the role of relative under-dosing.
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Introduction
In post-menopausal women, obesity, as measured by body
mass index (BMI) or waist–hip ratio (WHR), is a risk
factor for the development of new cases of breast cancer
[1]. In pre-menopausal women, the evidence is less clear-
cut: some reviews have reported a weak negative associa-
tion with general obesity, as measured by BMI [2, 3];
whereas others have reported a positive association with
central obesity, as measured by WHR [4, 5]. Obesity also
seems to affect survival in women who have already been
diagnosed with breast cancer; early studies have been
summarised in two meta-analyses.
The first of these included 14 studies [6] which enrolled
women diagnosed with breast cancer between 1968 and
1989. It reported a pooled estimate for the hazard ratio
(HR) for obese versus non-obese women (based on BMI)
of 1.6 (95% confidence interval (CI) 1.4, 1.8). The second
meta-analysis [7] included 12 studies which enrolled
patients from 1968 to 1991. The pooled estimate of the HR
(based on BMI) was also 1.6 (95% CI 1.2, 2.0). There are
now more than 40 published studies on the association
between obesity and breast cancer survival (including a
few studies that used WHR). Consequently, the primary
aim of this study was to conduct a meta-analysis that
included the more recent studies. Our hypothesis was that
women who were obese at the time of diagnosis of invasive
breast cancer, had worse overall or breast cancer specific
survival than non-obese women.
Methods
Search strategy
A systematic search of MEDLINE, EMBASE and CI-
NAHL, from inception to December 2009, was used to
identify studies evaluating the effects of obesity on sur-
vival in cancer patients. The search strategy included key
terms for cancer (neoplasms OR cancer OR tumour),
AND obesity (body size OR overweight OR bodyweight
OR obesity), AND survival or prognosis (survival analysis
OR survival rate OR proportional hazards model OR
survival OR prognosis). All search terms were ‘exploded’
in conjunction with using a keyword search. The search
was limited to English language papers that included
adults (age C 18 years). The reference lists of all eligible
articles and reviews were also scanned to identify addi-
tional relevant studies. All cancer studies were included
so as not to miss any results for breast cancer that might
have been reported as part of a larger study that included
other cancer types. Based on our knowledge of the liter-
ature, we anticipated that most of the identified studies
would be cohort studies; however, all study designs were
in scope.
Study selection
Studies were eligible for inclusion if they contained ori-
ginal data analysis, evaluated overall survival or breast
cancer specific survival in a cohort of newly diagnosed
breast cancer patients; and additionally assessed obesity
status at or around the time of first diagnosis. We did not
include studies that assessed the relationship between sur-
vival and weight gain or weight loss after diagnosis. We
concentrated on survival as the outcome, rather than
recurrence; our reasoning was that date of death is more
likely to be measured accurately and that results for sur-
vival are easier to interpret than those for recurrence
[8–11]. Figure 1 describes the search and study selection
process.
Data extraction and quality assessment
Articles were reviewed independently by two of us and
data items extracted as per Supplementary Table 1. Dis-
agreements were settled by consensus or a third reviewer
for adjudication. To assess quality we abstracted informa-
tion on the study population, measurement of obesity,
ascertainment of survival and adjustment for confounding
(Supplementary Table 2). If more than one adjusted HR
was reported, the most adjusted HR was extracted.
Data synthesis and statistical analysis
To avoid overlapping patient populations, comparisons
between studies were made on recruitment years, data
source and geographic location. If a patient population was
found to overlap, the data with the most comprehensive
population was included. This resulted in the exclusion of
one article from the meta-analysis [12].
Adjusted HR estimates were pooled using random
effects meta-analysis [13]. I2 was used to assess hetero-
geneity across studies [14]. Pre-specified analyses were
conducted to examine differences in survival for obese
versus non-obese women with breast cancer in different
strata defined according to how survival was measured
(overall or breast cancer specific), how obesity was mea-
sured (BMI or WHR), study design (treatment cohort or
observational cohort), period of diagnosis (pre-1995 or
post-1995) and menopausal status. These stratified analyses
were conducted by comparing pooled HRs in each stratum,
and P-values for each comparison were obtained using
random effects meta-regression [15]. Publication bias was
assessed using a funnel plot and trim-and-fill method [16].
All analyses were conducted using Stata 10 [17].
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Funding source
There was no external funding for this study. Resources
were provided by the authors’ institutions.
Results
The literature search identified 3566 citations of which 45
met the criteria for inclusion in the systematic review. The
main reason for exclusion was that the study evaluated
breast cancer incidence or mortality among cohorts of
women defined according to obesity status, without breast
cancer at inception; rather than assessing survival in cohorts
of patients newly diagnosed with breast cancer (Fig. 1).
Description of studies
The 45 studies included women diagnosed with breast
cancer across the years 1963–2005. Thirty-nine were
observational cohorts, while six were treatment cohorts.
The studies had been conducted in the United States (23),
Europe (11), Canada (4), Asia (2), Africa (1), Australia (1),
New Zealand (1) and multiple countries (2). Sample size
ranged from 100 to 424168, with a median of 1192.
Three of the studies used both BMI and WHR, 40 used
BMI alone, one used WHR alone and one used tables of
ideal weight for height. Seventeen of the studies used
height and weight based on self-report; in the others BMI
was based on height and weight, which were measured by
investigators or obtained from medical records. In two
studies the WHR measurements were obtained by investi-
gators, and in the other two studies WHR was estimated
using self-reported data. A variety of cut points were used
to categorise BMI. Most common was C30 kg/m2 versus
\25 kg/m2, which was used in 12 of the 43 studies that
reported BMI. Other various cut points were either based
on quartiles or tertiles of the observed distribution of BMI
for that particular study. Slightly different cut points were
used for each of the four studies that reported WHR
(Supplementary Table 1). Studies used death registries
(n = 28), medical records (n = 3) and active follow-up
(n = 8) to ascertain vital status and six did not report the
method of outcome ascertainment.
All studies had a median follow-up time of at least
4 years, with two studies having a median follow-up time
of more than 14 years. Adjustment for potential con-
founding was not consistent across studies: four studies
only provided unadjusted results and another 10 did not
account for at least age (or menopausal status) and stage
(using, for instance, restriction, stratification or statistical
modelling). Some studies adjusted for prognostic factors
such as oestrogen receptor (ER) status, progesterone
receptor (PR) status, tumour grade and treatment (e.g.
tamoxifen use); others did not (Supplementary Table 1).
Only one study adjusted for diabetes [18] and one other
study excluded patients with diabetes [19].
Meta-analysis
One of the identified studies [20] could not be included in
the meta-analysis because it reported odds ratios. It was a
138 eligible titles 
45 eligible abstracts 
 
53 unsuitable  exclusion A 
24 unsuitable  exclusion B 
14 unsuitable  exclusion C 
  1 unsuitable  exclusion D  
  1 unsuitable  exclusion E 
Abstracts 
screened for 
eligibility 
3566 Results from  
MEDLINE, EMBASE, CINAHL & 
reference lists 
45 Articles 
assessed for 
eligibility for 
meta-analysis 
 
Total articles included in meta-
analysis = 43 
Fig. 1 Study selection. Note: exclusion criteria A—studies that did
not evaluate a prognostic outcome (all-cause mortality or breast
cancer specific survival/mortality) in breast cancer patients, exclusion
criteria B—studies that did not measure obesity status at or around the
time of breast cancer diagnosis, exclusion criteria C—studies which
did not report original data, exclusion criteria D—studies which used
recurrent breast cancer cases (rather than newly diagnosed cases);
exclusion criteria E—studies which contained a repeated analysis in a
single population
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study of 301 post-menopausal women diagnosed with
breast cancer from 1977 to 1985. The adjusted odds ratio
was 1.37 (95% CI: 0.73, 2.56) for BMI C 27 kg/m2 versus
BMI \ 27 kg/m2, indicating worse survival for obese
patients. Statistical adjustment was for age, stage, ER status
and level of treatment.
Another study [21] could not be included in the meta-
analysis because it reported 5- and 10-year survival, rather
than HRs. This was a follow-up of a phase II trial of
adjuvant chemotherapy in women with node-positive
breast cancer. Obesity was defined as BMI C 30 kg/m2
and obese women had lower 10 year survival (42% sur-
vival) than women of normal (BMI \ 30) weight (53%).
The meta-analysis of the remaining 43 studies showed
poorer survival among obese compared with non-obese
women with breast cancer, which was similar for overall
survival (HR = 1.33; 95% CI: 1.21, 1.47) (Fig. 2) and breast
cancer specific survival (HR = 1.33; 95% CI: 1.19, 1.50)
(Fig. 3). The survival differential varied only slightly,
depending on whether BMI (1.33; 1.23, 1.44) or WHR (1.31;
1.14, 1.50) was used as the measure of obesity. There were
larger differences by whether the woman was pre-meno-
pausal (1.47) or post-menopausal (1.22); whether the cohort
included women diagnosed before (1.31) or after 1995
(1.49); or whether the women were in a treatment (1.22) or
observational cohort (1.36), but none of the differences were
statistically significant (Table 1).
There was arguably a lack of medium-sized, negative
studies on the funnel plot (Supplementary Figure 1),
however, accounting for this using the trim-and-fill method
gave a HR = 1.23 (95% CI: 1.11, 1.37), indicating that the
detrimental effect of obesity on breast cancer survival is
robust to potential publication bias.
Because studies used different methods to account for
confounding, we conducted a series of post hoc sensitivity
analyses, as opposed to our pre-specified sensitivity analy-
ses. After excluding univariate estimates (n = 4) the HR for
overall survival was 1.29 (1.18, 1.42). We then excluded all
studies that did not adjust (or restrict) at least by age or
menopausal status, in addition to stage at diagnosis (n = 10)
and obtained HR 1.30 (1.21, 1.40). Next, we excluded
studies that did not additionally adjust for ER, PR or HER-2
status (n = 12) and obtained HR 1.28 (1.16, 1.40).
We also compared HRs for studies that measured height
and weight to obtain BMI (n = 25) and those that used
self-reported height and weight (n = 17). There was little
Overall  (I-squared = 72.7%, p = 0.000)
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HR (95% CI) (log scale)
Fig. 2 Meta-analysis and
pooled hazard ratio of the effect
of obesity on overall survival in
breast cancer patients. Note: 33
studies provided 35 estimates.
a Pre-menopausal women only,
b post-menopausal women only
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difference in the HR for measured 1.38 (1.23, 1.55); or
self-report 1.40 (1.12, 1.76).
A potential source of heterogeneity is that different
studies used different cut points for BMI and WHR (Sup-
plementary Table 1). We conducted on post hoc sensitivity
analysis on just the 18 studies that used the WHO definition
of obesity (30? kg/m2) versus the reference category of
\25 kg/m2 (12 studies) or 18.5–24.9 (4 studies) or 20–24.9
(2 studies) and obtained HR = 1.35. We then analysed just
the 12 studies that used \25 versus 30? and obtained
HR = 1.37. We could not do a similar analysis for WHR
because all four of these studies used different cut points
(Supplementary Table 1).
Discussion
In this meta-analysis of 43 studies, survival among obese
women with breast cancer was worse than survival among
non-obese women (HR = 1.33). The pooled estimate of a
33% increase in the rate of death among obese women is
smaller than the 60% increase (HR = 1.6) reported by the
two earlier meta-analyses [6, 7]. This regression-to-the-
truth effect is common as evidence accumulates [22].
The obesity effect was larger in pre-menopausal (1.47)
than post-menopausal (1.22), women but the difference
was not statistically significant. Post hoc power calcula-
tions indicate that more than 50 studies with a sample size
of 1192 (the median sample size in this meta-analysis)
would be needed in each stratum to show that a HR of 1.47
was statistically significantly different from 1.22. There-
fore, obesity might be a stronger determinant of survival in
pre-menopausal as opposed to post-menopausal women,
but this meta-analysis did not have the statistical power to
show it definitively.
Most studies used BMI as a definition of obesity.
However, BMI is a relationship of weight to height, not
necessarily fatness, and definitions of obesity or ‘leanness’
based on BMI may not be accurate predictors of response
to metabolic stress [23]. There was only a minor difference
according to whether BMI (1.33) or WHR (1.31) was used
as the measure of obesity, however, only four analyses
used WHR. Also, we could not pool results for WHR by
menopausal status because only one study stratified by
menopausal status (pre-menopausal HR = 1.2; post-men-
opausal HR = 3.3) [24], and one study included only pre-
menopausal women (HR = 1.52) [25]. The other two
studies did not stratify by menopausal status (HR = 1.38;
HR = 1.1) [26, 27].
In randomised control trials (RCT), doses of chemo-
therapy are given according to a pre-specified protocol,
whereas in everyday practice, clinicians may reduce the
dose in obese women because of concern for toxicity if
appropriate dose for body surface area (BSA) is given;
applying empiric dose reductions to ‘cap’ the BSA at 2 m2,
or using ideal rather than actual body weight to calculate
BSA [28, 29]. The results of this meta-analysis suggest, but
do not definitively show, that some of the obesity effect
might be due to such under-dosing. The pooled HR from
treatment cohorts (1.22) was less than from observational
Overall  (I-squared = 58.1%, p = 0.001)
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Fig. 3 Meta-analysis and
pooled hazard ratio of the effect
of obesity on breast cancer
specific survival in breast cancer
patients. Note: 15 studies
provided 16 estimates. a Pre-
menopausal women only,
b study reported HR per one
unit increase in BMI as a
continuous variable and was
converted to HR per 5 unit
increase in BMI for the purpose
of this meta-analysis, c post-
menopausal women only
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cohorts (1.36), but the difference was not statistically sig-
nificant. There were only seven analyses of treatment
cohorts, therefore, as for menopausal status, the lack of a
statistically significant difference might reflect low statis-
tical power rather than the absence of a real effect.
The identified studies enrolled women diagnosed with
breast cancer over a long period: 1963–2005, but the
obesity effect did not vary much over that time. Specifi-
cally, the obesity effect was slightly higher post-1995
(HR = 1.49) compared to pre-1995 (1.31), but the differ-
ence was not statistically significant.
Limitations
It is possible that not all relevant studies were included,
however, the search strategy was broad and references
from each of the included studies were checked.
Only non-randomised cohort studies or secondary, post
hoc analyses of treatment cohorts were identified for
inclusion. Meta-analyses of such studies are prone to biases
and confounding factors that are inherent in the original
studies [30]. When extracting data we took the most
adjusted estimate. Sensitivity analyses excluding studies
that did not adjust for at least stage, age (or menopausal
status), ER status or the use of hormone replacement
therapy (HRT) suggested that the obesity effect was robust
to potential confounding.
Mechanism of action of obesity on breast cancer
survival
When we excluded studies that did not adjust for stage (and
age or menopausal status) we obtained HR = 1.31.
Therefore, advanced stage at diagnosis cannot be the
explanation for the poor survival of obese patients despite
the knowledge that obese women undergo less breast
cancer screening [31].
The obesity effect was of similar size for overall survival
and breast cancer specific survival (HR for both 1.33). This
result is not consistent with the hypothesis that obese
women with breast cancer have poorer overall survival
because of a higher risk of non-cancer causes of death [32].
Obese women are at higher risk for a second primary
breast cancer [33] and this could lead to poorer breast
cancer specific survival, unrelated to an increased risk of
death from the first breast cancer. However, this is unlikely
to account for all the increased risk of breast cancer specific
death, identified in this meta-analysis, because the risk of a
second primary is small, even for obese women. For
example, in the recent study by de Azambuja et al. [34],
only 3.1% of obese women developed a second primary
breast cancer within 5 years of their first primary; the
corresponding percentage for non-obese women was 2.2%.
There are two other hypotheses (i.e. besides more
advanced stage and higher risk of second primary) which
may explain why obese breast cancer patients have worse
survival. Firstly, obese patients may have more biologi-
cally aggressive tumours. Obesity is associated with the
upregulation of a number of cellular proliferation pathways
[35], and consequently obese patients may have increased
tumour cell proliferation and metastasis due to an unde-
fined adipokine effect on tumour cells [36]. For example,
leptin, an adipocytokine, is produced mainly by white
adipose tissue and is known to act as a growth factor in
cancer, including cancer of the breast [37]. It promotes
angiogenesis, potentially directly stimulating growth of
Table 1 Sensitivity analyses of
pooled hazard ratios of the
effect of obesity on survival in
breast cancer patients
* P-value for pre- versus post-
menopausal women (not
including studies which did not
stratify by menopausal status)
Subgroup No. of estimates Pooled HR (95% CI) I2% P-value
Survival measure
All-cause 36 1.33 (1.21–1.47) 73 (62–80) 0.91
Breast cancer specific 19 1.33 (1.19–1.50) 58 (30–75)
Obesity measure
BMI 55 1.33 (1.23–1.44) 70 (60–77) 0.95
WHR 6 1.31 (1.14–1.50) 0 (0–75)
Study design
Observational cohort 48 1.36 (1.23–1.49) 73 (64–79) 0.53
Treatment cohort 7 1.22 (1.14–1.31) 0 (0–71)
Menopausal status
Pre-menopausal 16 1.47 (1.19–1.83) 68 (46–81) 0.25*
Post-menopausal 12 1.22 (0.95–1.57) 70 (47–84)
Both 36 1.33 (1.23–1.43) 61 (45–73)
Year of diagnosis
Pre-1995 30 1.31 (1.16–1.46) 76 (66–83) 0.17
Post-1995 11 1.49 (1.31–1.68) 0 (0–60)
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breast cancer cells, possibly translating to reduced survival
[38]. Insulin-like Growth Factor-1 (IGF1) also inhibits
apoptosis, and higher fasting insulin concentrations are
correlated with increased recurrences and decreased sur-
vival in breast cancer [19].
It has also been postulated that adipose tissue production
of oestrogens may contribute to more biologically aggres-
sive ER-positive tumours in post-menopausal women
because BMI is directly related to circulating oestrogen
levels [39]. However, in studies of women receiving anti-
hormonal treatment, BMI did not appear to be an inde-
pendent prognostic factor, suggesting that excessive
endogenous oestrogens are not responsible for the adverse
effect of obesity on survival [11, 40].
Secondly, several studies have shown that obese patients
are more likely to receive reduced doses of chemotherapy
compared to normal weight women. A large retrospective
cohort study of breast cancer patients conducted by Griggs
et al. [41] found that overweight and obese women were
more likely to receive intentionally reduced doses of che-
motherapy compared with women of normal weight,
despite several studies finding that obese women receiving
full doses of chemotherapy experienced no more toxicity
than normal weight patients [42, 43]. Obese patients may
also have a relative reduction in cancer treatment due to
comorbidities such as cardiovascular or renal disease or
local toxicity from radiation therapy. A related hypothesis is
that obesity has an effect on metabolism of cytotoxic drugs;
for example, through an effect on the p450 system [44].
Implications for further research
There was limited information available about the possible
joint effect of diabetes and obesity on survival. Only one
study [18] adjusted for diabetes (in addition to stage, age,
ER status, smoking status and hypertension) and reported
adjusted HR = 1.14 for overall survival and 1.16 for breast
cancer specific survival. Another study excluded diabetes
[19] and reported adjusted HR = 1.78 (overall survival). A
recent meta-analysis of four studies examining effect of
diabetes on overall survival among women with breast
cancer reported a pooled HR of 1.61 [45]. However, the
studies did not adjust or stratify by obesity, which shares
many risk factors with diabetes so the effect of one on the
other is relevant and worthy of further investigation.
There was also limited information about whether the
obesity effect varies by different chemotherapy regimens.
Eight studies adjusted for whether the women received any
chemotherapy at all, without specifying the type of che-
motherapy (i.e. any chemotherapy: yes/no) and without
providing analyses stratified into ‘‘chemotherapy’’ and ‘‘no
chemotherapy’’ (Supplementary Table 1). Given the broad,
non-specific nature of this statistical adjustment and the
lack of stratified analyses, it was not possible to explore the
issue of obesity–chemotherapy interaction using the cur-
rently available evidence.
Several studies adjusted for prognostic factors such as
HER-2 status, ER status, PR status, p53 and HRT-use but as
for type of chemotherapy, no studies presented stratified
analyses, so it was not possible to assess whether these
prognostic factors modified the effect of obesity on survival
and further work along these lines would also be useful.
It is currently unclear whether post-diagnosis weight
reduction modifies the association between obesity at
diagnosis and poor survival. A recent RCT showed that
reducing dietary fat intake improves relapse-free survival
of breast cancer, despite only a modest effect on weight
[46]. A RCT assessing the effect of a weight loss and
physical activity intervention on survival from breast can-
cer is also planned [47].
Conclusion
Based on the results of this meta-analysis, women should
be advised that keeping their weight within normal limits
will have benefits should they develop breast cancer.
However, no study has elucidated the causal mechanism
and there is currently no evidence that weight loss after
diagnosis improves survival. Consequently, there is cur-
rently no reason to place the additional burden of weight
loss on women already burdened with a diagnosis of can-
cer. Further research should concentrate on assessing both
whether factors such as diabetes, ER status or type of
chemotherapy regimen modify the obesity effect and on
understanding the causal mechanism, in particular the role
of relative under-dosing.
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